PHA Fundamental Analysis - PREMIER HEALTH OF AMERICA IN

Fundamental Rating

PHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 14 industry peers in the Health Care Providers & Services industry. PHA may be in some trouble as it scores bad on both profitability and health. PHA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PHA has reported negative net income.

In the past year PHA had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: PHA reported negative net income in multiple years.

PHA had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

PHA has a Return On Assets of -20.74%. This is in the lower half of the industry: PHA underperforms 71.43% of its industry peers.

		Industry Rank	Sector Rank
ROA	-20.74%
ROE	N/A
ROIC	N/A

ROA(3y)-6.71%

ROA(5y)-3.2%

ROE(3y)-105.76%

ROE(5y)-61.59%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of PHA (16.12%) is worse than 78.57% of its industry peers.

In the last couple of years the Gross Margin of PHA has declined.

The Profit Margin and Operating Margin are not available for PHA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	16.12%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-10.25%

GM growth 5Y-4.32%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PHA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for PHA has been increased compared to 1 year ago.

Compared to 5 years ago, PHA has more shares outstanding

PHA has a worse debt/assets ratio than last year.

2.2 Solvency

PHA has an Altman-Z score of 0.54. This is a bad value and indicates that PHA is not financially healthy and even has some risk of bankruptcy.

PHA has a Altman-Z score of 0.54. This is in the lower half of the industry: PHA underperforms 71.43% of its industry peers.

The Debt to FCF ratio of PHA is 5.80, which is a neutral value as it means it would take PHA, 5.80 years of fcf income to pay off all of its debts.

PHA has a Debt to FCF ratio of 5.80. This is in the better half of the industry: PHA outperforms 71.43% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	5.8
Altman-Z	0.54

ROIC/WACCN/A

WACC9.87%

2.3 Liquidity

PHA has a Current Ratio of 0.44. This is a bad value and indicates that PHA is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of PHA (0.44) is worse than 64.29% of its industry peers.

A Quick Ratio of 0.44 indicates that PHA may have some problems paying its short term obligations.

PHA has a Quick ratio of 0.44. This is in the lower half of the industry: PHA underperforms 64.29% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.44
Quick Ratio	0.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PHA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.76%.

The Revenue for PHA has decreased by -22.61% in the past year. This is quite bad

PHA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.58% yearly.

EPS 1Y (TTM)7.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%58.24%

Revenue 1Y (TTM)-22.61%

Revenue growth 3Y33.41%

Revenue growth 5Y68.58%

Sales Q2Q%-47.18%

3.2 Future

The Earnings Per Share is expected to grow by 11.79% on average over the next years. This is quite good.

PHA is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.61% yearly.

EPS Next Y40.21%

EPS Next 2Y18.19%

EPS Next 3Y11.79%

EPS Next 5YN/A

Revenue Next Year-20.72%

Revenue Next 2Y-10.85%

Revenue Next 3Y-5.61%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

PHA's Enterprise Value to EBITDA is on the same level as the industry average.

Based on the Price/Free Cash Flow ratio, PHA is valued cheaper than 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	0.14
EV/EBITDA	198.35

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y18.19%

EPS Next 3Y11.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PHA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PREMIER HEALTH OF AMERICA IN

TSX-V:PHA (11/26/2025, 7:00:00 PM)

0.02

+0.01 (+33.33%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)08-21 2025-08-21

Earnings (Next)12-18 2025-12-18

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners42.81%

Ins Owner ChangeN/A

Market Cap1.11M

Revenue(TTM)114.64M

Net Income(TTM)-11.21M

Analysts40

Price Target0.2 (900%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-46.08%

Min Revenue beat(2)-52.2%

Max Revenue beat(2)-39.96%

Revenue beat(4)0

Avg Revenue beat(4)-35.99%

Min Revenue beat(4)-52.2%

Max Revenue beat(4)-23.88%

Revenue beat(8)1

Avg Revenue beat(8)-19.64%

Revenue beat(12)2

Avg Revenue beat(12)-14.13%

Revenue beat(16)5

Avg Revenue beat(16)-4.15%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.01
P/FCF	0.14
P/OCF	0.11
P/B	N/A
P/tB	N/A
EV/EBITDA	198.35

EPS(TTM)-0.2

EYN/A

EPS(NY)-0.12

Fwd EYN/A

FCF(TTM)0.14

FCFY701.85%

OCF(TTM)0.19

OCFY935.33%

SpS2.07

BVpS-0.09

TBVpS-0.63

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-20.74%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	16.12%
FCFM	6.8%

ROA(3y)-6.71%

ROA(5y)-3.2%

ROE(3y)-105.76%

ROE(5y)-61.59%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-10.25%

GM growth 5Y-4.32%

F-Score4

Asset Turnover2.12

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	5.8
Debt/EBITDA	4.38
Cap/Depr	33.89%
Cap/Sales	2.26%
Interest Coverage	N/A
Cash Conversion	4534.5%
Profit Quality	N/A
Current Ratio	0.44
Quick Ratio	0.44
Altman-Z	0.54

F-Score4

WACC9.87%

ROIC/WACCN/A

Cap/Depr(3y)35.11%

Cap/Depr(5y)76.64%

Cap/Sales(3y)1.6%

Cap/Sales(5y)1.86%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)7.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%58.24%

EPS Next Y40.21%

EPS Next 2Y18.19%

EPS Next 3Y11.79%

EPS Next 5YN/A

Revenue 1Y (TTM)-22.61%

Revenue growth 3Y33.41%

Revenue growth 5Y68.58%

Sales Q2Q%-47.18%

Revenue Next Year-20.72%

Revenue Next 2Y-10.85%

Revenue Next 3Y-5.61%

Revenue Next 5YN/A

EBIT growth 1Y-862.2%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-41.28%

EBIT Next 3Y-11.94%

EBIT Next 5YN/A

FCF growth 1Y238.34%

FCF growth 3Y400.47%

FCF growth 5Y56.2%

OCF growth 1Y360.3%

OCF growth 3Y44.26%

OCF growth 5Y70.26%

PREMIER HEALTH OF AMERICA IN / PHA.CA FAQ

What is the fundamental rating for PHA stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHA.CA.

What is the valuation status for PHA stock?

ChartMill assigns a valuation rating of 2 / 10 to PREMIER HEALTH OF AMERICA IN (PHA.CA). This can be considered as Overvalued.

How profitable is PREMIER HEALTH OF AMERICA IN (PHA.CA) stock?

PREMIER HEALTH OF AMERICA IN (PHA.CA) has a profitability rating of 1 / 10.

Can you provide the expected EPS growth for PHA stock?

The Earnings per Share (EPS) of PREMIER HEALTH OF AMERICA IN (PHA.CA) is expected to grow by 40.21% in the next year.

PREMIER HEALTH OF AMERICA IN (PHA.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PREMIER HEALTH OF AMERICA IN / PHA.CA FAQ

What is the fundamental rating for PHA stock?

What is the valuation status for PHA stock?

How profitable is PREMIER HEALTH OF AMERICA IN (PHA.CA) stock?

Can you provide the expected EPS growth for PHA stock?